哌罗匹隆对帕罗西汀抗抑郁增效作用的研究

目的探讨哌罗匹隆对选择性5-羟色胺（5-hydroxytryptamine，5-HT）再摄取抑制剂帕罗西汀抗抑郁的增效作用和安全性。方法将80例单一使用帕罗西汀治疗抑郁症疗效不佳的患者随机分均为2组。研究组40例，联合哌罗匹隆治疗；对照组40例，联合安慰剂腺苷钴胺治疗。疗程共6周，在治疗前及治疗2、4、6周后使用汉密尔顿抑郁量表（HamihonDepressionScale，HAMD）评定疗效，使用副反应量表（TreatmentEmergentSymptomScale，Tess）评定药物不良反应。结果研究组治疗2周后HAMD评分比治疗前明显降低（P〈0．05），治疗6周后痊愈16例，显效10例，HAMD评分比治疗前明显降低（P〈0．05）。对照组治疗2周后HAMD评分与治疗前比较无明显差异（P〉0．05），治疗6周后治愈痊愈1例，显效2例，HAMD评分与治疗前比较无明显降低（P〉O．05）。两组在治疗前及治疗2、4、6周后TESS评分无统计学差异（P〉0．05），研究组和对照组分别有4例和16例患者需服用艾司唑仑辅助睡眠，研究组出现失眠的比例明显少于对照组（P〈0．05）。结论哌罗匹隆可增加帕罗西汀治疗抑郁症的疗效，未增加不良反应，安全性好，且有促进睡眠的作用。

Synergism Effect of Perospirone on Paroxetine in Antidepressant Treatment

Objective To discuss the synergism and safety of perospirone on paroxetine which is the selective sero- tonin reuptake inhibitor in antidepressant treatment. Methods Eighty patients whose feedback of only paroxetine antide- pressant treatment was not well were randomly divided into study group （40 cases） combined with perospirone therapy and control group （40 cases） combined with cobamamide therapy. The treatment courses lasted for 6 weeks. The efficacy was evaluated by Hamilton Depression Scale （HAMD） before treatment, and at 2, 4 and 6 weeks of treatment. Treat- ment Emergent Symptom Scale （TESS） was applied to record drug adverse reaction. Results In the study group, after 2 weeks of treatment, the HAMD score was significantly decreased compared with that before treatmerlt （P〈0. 05）. Sixteen cases recovered after 6 weeks of treatment and 10 cases were improved whose HAMD scores were significantly de- creased compared with those before treatment （P〈0. 05）. In the control group, the HAMD score had no significant difference compared with that before treatment （P〉0. 05）. One case recovered after 6 weeks of treatment and 2 cases were improved. HAMD scores had no significant difference compared with those before treatment （P 〉 0. 05）. Both groups had no significant difference in TESS scores （P〉0. 05） at all timepoints. Four cases in the study group and 16 ca- ses in the control group needed estazolam to help sleeping. The incidence of agrypnia in the study group was lower than that in the control group （P〈0. 05）. Conclusion Perospirone can promote the effect of paroxetine in antidepressant treat- ment with safety, no additional adverse reactions and effects to help sleeping.